Podcasts about patient reported outcomes

The Journal of Arthroplasty: The Cut brings you another very special episode based on Knee Society Proceedings that highlight important research about knee arthroplasty. In this episode of The Cut, our host Kimberly K. Tucker, MD welcomed our guests Antonia F. Chen, MD, MBA and Andrew Engh, MD to discuss Patient Reported Outcomes and what this means for you now that Medicare has made them a requirement in quality benchmarks. In this podcast, we review two award-winning studies. The first study dives into the various ways to optimize patient reported outcome collection within health systems. Dr. Chen shares what she feels is the most important change hospitals should focus on to make patient reported outcome collection both clinically meaningful and operational sustainable. The other award-winning paper discusses paper vs. electronic data capture in knee arthroplasty. Learn if compared to paper forms, does electronic data collection increase follow-up rates or improve data quality at lower costs. I think you’ll find this recording of JOA: The Cut to be filled with lots of valuable nuggets that can possibly shape and improve your practice. Thanks for listening to The Journal of Arthroplasty’s: The Cut! In This Episode: Antonia F. Chen, MD, MBA Andrew Engh, MD Kimberly K. Tucker, MD The post Getting the Most out of Patient Reported Outcomes first appeared on AAHKS.

Die Folge wurde durch die freundliche Unterstützung der Novartis Pharma GmbH ermöglicht. MS-Biomarker im Verlauf können dabei helfen, Krankheitsaktivität sichtbar zu machen – auch dann, wenn die Multiple Sklerose nach außen ruhig wirkt und keine Schübe auftreten. Denn Schübe sind oft nur die Spitze des Eisbergs. In dieser Folge von spreche ich mit Prof. Dr. Katja Akgün, Neurologin und MS-Expertin, darüber, welche Biomarker heute zur Verlaufskontrolle eingesetzt werden und warum regelmäßige, standardisierte Messungen so wichtig sind. Wir schauen gemeinsam darauf, wie Ärzt:innen und Patient:innen auch schleichende Veränderungen frühzeitig erkennen können – im MRT, im Blut, im Alltag und mithilfe moderner Untersuchungsmethoden. Im Gespräch geht es unter anderem um: warum Biomarker bei MS so wichtig sind, auch ohne spürbare Symptome welche Rolle das MRT bei der Verlaufskontrolle spielt wie sich ein echter Schub von vorübergehenden Verschlechterungen unterscheiden lässt welche Bedeutung Blutmarker wie sNfL und GFAP haben was der Liquor bei der Diagnose leistet – und warum Blutmarker für den Verlauf praktischer sind wie OCT, kognitive Tests und digitale Daten Hinweise auf schleichende Veränderungen geben warum Patient-Reported Outcomes und das eigene Erleben eine zentrale Rolle spielen

In this episode of The Cardiac Recovery Room, moderator Vicki Morton, Director of Clinical and Quality Outcomes at Providence Anesthesiology Associates in North Carolina, USA, spoke with Alexander Gregory, a cardiovascular anesthesiologist and assistant professor in the Department of Anesthesiology, Perioperative and Pain Medicine, and the Libin Cardiovascular Institute at the Cumming School of Medicine, University of Calgary, Canada, and Dr. V. Seenu Reddy, a cardiothoracic surgeon at HCA's TriStar Cardiovascular Surgery in Nashville, Tennesee, USA, about the 10 things they hate about Enhanced Recovery After Surgery (ERAS).   Chapters 00:00 Introduction  01:38 Overcomplication  05:29 Simple Barriers  08:54 Change Obstructionists  10:52 Status Quo  12:49 Messing with Protocol  14:21 Giving Up on Protocol  16:48 Need for Patient-Reported Outcomes  19:18 Struggle Into Cardiac Subspecialty  21:30 Takeaways  The goal of this discussion was to identify specific challenges and propose potential solutions. They emphasize the importance of having two leaders—a champion and a co-champion—to effectively guide ERAS initiatives. Additionally, they discuss creating standing orders and issues related to microbarriers and resistance to change. They also highlight the need for customization of protocols, acknowledging the differences between surgeons who utilize ERAS and those who do not, as well as the tendency to maintain the status quo. Patient perspectives are another key focus, with a call to implement changes that enhance tracking and monitoring of patient outcomes. Furthermore, they explore the role of technology designed for patients, as well as applying ERAS principles to surgeries that fall “outside of the box.”   The Cardiac Recovery Room is the place to hear the conversations colleagues are having after the meetings. Each month, a new episode will be released featuring a leadership panel from the ERAS Cardiac Society.  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

In today's episode, we had the pleasure of speaking with Sikander Ailawadhi, MD, and Beth Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO, about the potential clinical implications of the phase 3 IRAKLIA (NCT05405166) and phase 2 IZALCO (NCT05704049) studies, which investigated the use of isatuximab-irfc (Sarclisa) administered via an on-body delivery system in patients with relapsed/refractory multiple myeloma. Ailawadhi is a consultant in the Division of Hematology/Oncology in the Department of Internal Medicine, a consultant in the Department of Cancer Biology, and a professor of medicine at Mayo Clinic in Jacksonville, Florida. Faiman is a nurse practitioner in the Multiple Myeloma Program at Cleveland Clinic in Ohio. In our exclusive interview, Ailawadhi and Faiman discussed the rationale for efforts to bring isatuximab on-body injectors into the clinic, key patient-reported outcome findings from these studies, and how these findings may one day influence therapy administration across the broader multiple myeloma treatment paradigm.

With Sotiria Liori, Attikon University Hospital, National and Kapodistrian University of Athens - Greece and Julie De Backer, Ghent University Hospital - Belgium. In this episode, Sotiria Liori and Julie De Backer discuss heart failure in adult congenital heart disease patients — covering how congenital lesions and prior repairs shape epidemiology and mechanisms (ventricular remodeling, valvular and conduit dysfunction, arrhythmias), as well as clinical assessment with imaging, biomarkers, and hemodynamics. They outline management with guideline-directed therapy, rhythm considerations, indications for advanced therapies (MCS and transplant), and pregnancy counseling. The episode also highlights multidisciplinary care models and key evidence gaps. Proposed reading:  General Principles of Heart Failure Management in Adult Congenital Heart Disease. Tompkins R, Romfh A. Heart Failure Reviews. 2020;25(4):555-567. doi:10.1007/s10741-019-09895-x Chronic Heart Failure in Congenital Heart Disease: A Scientific Statement From the American Heart Association. Stout KK, Broberg CS, Book WM, et al. Circulation. 2016;133(8):770-801. doi:10.1161/CIR.0000000000000352. Relation Between New York Heart Association Functional Class and Objective Measures of Cardiopulmonary Exercise in Adults With Congenital Heart Disease. Das BB, Young ML, Niu J, et al. The American Journal of Cardiology. 2019;123(11):1868-1873. doi:10.1016/j.amjcard.2019.02.053.  Heart Failure and Patient-Reported Outcomes in Adults With Congenital Heart Disease from 15 Countries. Lu CW, Wang JK, Yang HL, Kovacs AH, et al; APPROACH‐IS consortium, the International Society for Adult Congenital Heart Disease (ISACHD) *.J Am Heart Assoc. 2022 May 3;11(9):e024993. doi: 10.1161/JAHA.121.024993. Epub 2022 Apr 26. Pharmacological Therapy in Adult Congenital Heart Disease: Growing Need, Yet Limited Evidence. Brida M, Diller GP, Nashat H, et al. European Heart Journal. 2019;40(13):1049-1056. doi:10.1093/eurheartj/ehy480. Advanced Heart Failure Therapies For Adults With Congenital Heart Disease: JACC State-of-the-Art Review. Givertz MM, DeFilippis EM, Landzberg MJ, et al. Journal of the American College of Cardiology. 2019;74(18):2295-2312.doi:10.1016/j.jacc.2019.09.004. A Review of Heart Transplantation for Adults With Congenital Heart Disease. McMahon A, McNamara J, Griffin M. Journal of Cardiothoracic and Vascular Anesthesia. 2021;35(3):752-762. doi:10.1053/j.jvca.2020.07.027. Heart Failure in Adult Congenital Heart Disease: From Advanced Therapies to End-of-Life Care. Crossland DS, Van De Bruaene A, Silversides CK, Hickey EJ, Roche SL. The Canadian Journal of Cardiology. 2019;35(12):1723-1739. doi:10.1016/j.cjca.2019.07.626. This 2025 HFA Cardio Talk podcast series is supported by Bayer AG in the form of an unrestricted financial support. The discussion has not been influenced in any way by its sponsor. 

Featuring an interview with Dr Kevin Kalinsky, including the following topics: Patient-Reported Outcomes from the TROPION-Breast01 Study (0:00) Pernas S et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Patient-reported outcomes from the TROPION-Breast01 study. ASCO 2024;Abstract 1006. Indirect Comparison of Sacituzumab Govitecan and Datopotamab Deruxtecan for Advanced Breast Cancer (5:04) Pathak N et al. Indirect comparison of sacituzumab govitecan (SG) and datopotamab deruxtecan (Dato-DXd) in advanced breast cancer (aBC): Safety and efficacy analysis. San Antonio Breast Cancer Symposium 2024;Abstract P1-02-02. BEGONIA: A Phase Ib/II Study of Datopotamab Deruxtecan with Durvalumab as First-Line Treatment for Unresectable Advanced Triple-Negative Breast Cancer (9:53) Schmid P et al. Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study. ESMO 2023;Abstract 379MO. Advances in the Use of TROP2-Targeted Antibody-Drug Conjugates for Breast Cancer: Mechanisms, Clinical Applications and Future Directions (15:35) Tong Y et al. Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: Mechanisms, clinical applications, and future directions. Front Immunol 2024;15:1495675. Abstract CME information and select publications

Virtual Course: November 6-8, 2025 (Course #2503269) Learn more and register at https://www.aaos.org/education/courses/2503269-3345/ Course Directors: J. Mark Melhorn MD FAAOS, Marilyn L. Yodlowski MD PhD FAAOS, and Barry Gelinas MD DC FIAIME Supplemental articles: Review article “A Comprehensive Review of Injury Causation Analysis Methodology for the Assessment of Workers' Compensation and Motor Vehicle Collision Injuries” from the March 1, 2025 issue JAAOS Global Research article “Workers' Compensation: The Burden on Healthcare Resource Utilization After Foot and Ankle Surgery” from the December, 2023 issue Research article “The Influence of Workers' Compensation Status on Patient-Reported Outcomes after Cervical Disc Arthroplasty at an Ambulatory Surgical Center” from the September 1, 2023 issue AAOS Now article “Why Workers' Compensation Expertise Still Matters for Orthopaedic Surgeons” 17:16-2023. AAOS Now article “Workers' Compensation Cases: Learn the Differences between ‘Medically Necessary,' ‘Reasonable,' and ‘Appropriate'" 15:28-29, 2021. The JAAOS Journal Club podcast series is brought to you by the Journal of the American Academy of Orthopaedic Surgeons and the AAOS Resident Assembly. The opinions expressed in the podcast are those of the speakers and not necessarily those of AAOS. The opinions, information, and discussions presented in the podcast are for general informational and educational purposes only.  The podcast is not intended to provide legal advice as each case and jurisdiction will vary.  Medical professionals should consult with their own attorney or an attorney involved in the claims process to address questions or concerns about any legal aspects associated with the patient evaluation.

In this episode of The Cleft Palate Craniofacial Journal podcast series, Pat Chibbaro, Multimedia Specialist, interviews Isabel A. Ryan and Jordan W. Swanson, authors of the CPCJ article entitled, "Patient-Reported Outcomes of Primary Cleft Rhinoplasty: A Long-Term Assessment Using CLEFT-Q" (coauthored by Jinggang J. Ng, Jusung Kim, Philip D. Tolley, Oksana A. Jackson, David W. Low, Scott P. Bartlett, Jesse A. Taylor, and Eric C. Liao).

In this episode, listen to Kelly Romo, PharmD, BCOP; and Shauna Kraft, PharmD, BCOP, share their takeaways from a live webinar on available emerging subcutaneous immunotherapy options for patients with cancer including:Basic mechanism of action and role of hyaluronidase in subcutaneous immunotherapy formulation and available dosing/schedulesAvailable pharmacodynamics/pharmacokinetics, efficacy, and safety data for subcutaneous immunotherapy formulationsCurrent and potential models for administration of subcutaneous immunotherapy in the inpatient setting and day-to-day considerationsPresenters:Kelly Romo, PharmD, BCOPManager, Oncology Medical Drug Management and Customer InitiativesBlue Cross Blue Shield MichiganDetroit, MichiganShawna Kraft, PharmD, BCOPClinical Pharmacist, SpecialistMichigan Medicine, Rogel Cancer CenterClinical Associate ProfessorUniversity of Michigan College of PharmacyAnn Arbor, MichiganResources:Consolidate your learning with a recording from an on-demand webcast, download the slides associated with this discussion, or read an expert text module or commentary on this topic. 

In this episode, listen to Kelly Romo, PharmD, BCOP; and Shauna Kraft, PharmD, BCOP, share their takeaways from a live webinar on available emerging subcutaneous immunotherapy options for patients with cancer including:Basic mechanism of action and role of hyaluronidase in subcutaneous immunotherapy formulation and available dosing/schedulesAvailable pharmacodynamics/pharmacokinetics, efficacy, and safety data for subcutaneous immunotherapy formulationsCurrent and potential models for administration of subcutaneous immunotherapy in the inpatient setting and day-to-day considerationsPresenters:Kelly Romo, PharmD, BCOPManager, Oncology Medical Drug Management and Customer InitiativesBlue Cross Blue Shield MichiganDetroit, MichiganShawna Kraft, PharmD, BCOPClinical Pharmacist, SpecialistMichigan Medicine, Rogel Cancer CenterClinical Associate ProfessorUniversity of Michigan College of PharmacyAnn Arbor, MichiganResources:Consolidate your learning with a recording from an on-demand webcast, download the slides associated with this discussion, or read an expert text module or commentary on this topic. 

Today, we're discussing patient reported outcomes - what are they, how can they be measured and how do they compare to other measures we often use to measure the success (or not) of research.  Remember, you can get in touch with us via clinical.research.intro@gmail.com. Please feel free to send questions, comments and compliments for Elyse to read out on the pod. It's fun to make Debbie squirm! Credit to our friend Sam Winnie for their awesome and cute music. Check out their work at https://www.samwinnie.com/ References https://www.jmir.org/2020/3/e12689/  https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-18#:~:text=A%20patient%2Dreported%20outcome%20(PRO,(Powers%20et%20al%202017).  https://www.gov.uk/guidance/patient-reported-outcomes-and-experiences-study#:~:text=Broadly%2C%20PROMs%20evaluate%20either%20the,pain%20or%20discomfort https://www.birmingham.ac.uk/research/centres-institutes/patient-reported-outcomes/prolearn/pros-in-trials#:~:text=Capturing%20Patient%2DReported%20Outcomes%20(PROs,and%20treatment%20on%20their%20life.  https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims 

Focal cartilage lesions are commonly associated with anterior cruciate ligament injuries. The long-term effect of these lesions on patient-reported outcomes after anterior cruciate ligament reconstruction (ACLR) remains unclear.   In conclusion, patients with concomitant partial- or full-thickness cartilage lesions reported significantly worse outcomes in all KOOS subscales 10 years after ACLR as compared with patients without cartilage lesions.     Click here to read the article.

Patient-reported outcomes (PROs) have become a critical tool for capturing the lived experience of multiple sclerosis (MS), offering a perspective that extends beyond traditional clinical and imaging metrics. As research increasingly prioritises real-world relevance and individualised care, PROs provide valuable insights into symptoms such as fatigue, mood changes, and cognitive decline—factors that often evade objective measurement but have a profound impact on quality of life. Professor Jan Hillert of Karolinska Institute in Sweden and chair of the Swedish MS Registry joins host Brett Drummond of MStranslate to discuss how patient reported data are being integrated into clinical trial design and observational studies. They also explore current limitations to their use and highlight best practices for validation and interpretation. 

In this episode of the Award-winning PRS Journal Club Podcast, 2025 Resident Ambassadors to the PRS Editorial Board – Christopher Kalmar, Ilana Margulies, and Amanda Sergesketter- and special guest, Lara Devgan, MD, MPH, discuss the following articles from the July 2025 issue: “A Prospective Comparison of Patient-Reported Outcomes after Facial Laser Resurfacing” by Arias, Gala, Stetz, et al. Read the article for FREE: https://bit.ly/FacialLzrPROs Special guest, Lara Devgan, MD, MPH is an internationally known aesthetic plastic surgeon practicing aesthetic surgery of the face, breast, and body as well as facial injectables in New York City. She attended Yale for her undergraduate education followed by Johns Hopkins for medical school and the Columbia/Cornell program for plastic surgery residency. She is the founder and CEO of the medical-grade skincare line Dr. Devgan Scientific Beauty, serves as a medical expert for ABC News, is an editorial consultant for the Lancet, and lectures internationally on aesthetic plastic surgery. READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCJuly25Collection The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS.

In Folge 71 des Podcasts „Mehr Einsatz Wagen“ sprechen wir mit Dr. Stefan Hess, dem Leiter des neuen Forschungsdatenzentrums am BfArM. Das Gespräch wurde im HealthCare MakerMobil auf der DMEA 2025 aufgezeichnet und führt uns mitten hinein in die Chancen und Herausforderungen rund um Gesundheitsdaten, Digitalisierung, Forschung und die elektronische Patientenakte (ePA).Im Zentrum steht die Frage, wie wir die Vielzahl an Versorgungsdaten – von Abrechnungsdaten über Laborwerte bis hin zu Wearables – nutzbar machen können: für bessere Forschung, präzisere Versorgung und eine informierte Gesellschaft.Schwerpunkte der Episode:Forschungsdatenzentrum am BfArM: Ziel, Funktionsweise und Datenarten – von Abrechnungsdaten bis ePA-Inhalten.Elektronische Patientenakte (ePA): Welche Daten fließen hinein? Was bedeutet das Opt-Out-Prinzip?Strukturierte vs. unstrukturierte Daten: Warum strukturierte Daten leichter auswertbar sind und wie KI bei der Erschließung hilft.Verknüpfung von Datenquellen: Wie pseudonymisierte Daten aus verschiedenen Sektoren sinnvoll zusammengeführt werden können.Neue Formen von Evidenz: Ergänzung klassischer Studien durch reale Versorgungsdaten – was wir über Subgruppen, Kontexte und Entscheidungen lernen können.Nutzenbewertung & Datengleichheit: Gleicher Datenzugang für Industrie und Bewertungsbehörden – und was das für Preis- und Bewertungslogik bedeutet.Demokratisierung von Forschung: Wie offene Datenräume Transparenz und Teilhabe fördern – auch für Patient:innen und Organisationen.Synthetische Daten und Statistik: Wie neue mathematische Methoden Datenlücken schließen und Forschung robuster machen können.Dirty Data und Signale: Warum verrauschte oder subjektive Daten wichtig für die Hypothesengenerierung sind.Gamification & Citizen Science: Wie man Menschen motiviert, Daten zu spenden – und was sie als Rückmeldung brauchen.Patient Reported Outcomes & Biografieforschung: Warum subjektives Erleben in der Forschung einen festen Platz braucht.Europäischer Gesundheitsdatenraum: Wie sich Deutschland in ein dezentrales, aber vernetztes System einfügt.Prävention & Beteiligung: Was die zunehmende Datenverfügbarkeit für die individuelle Gesundheitsvorsorge bedeutet – und welche Rolle Ärzt:innen dabei spielen.Fazit: Diese Folge zeigt, wie ein neuer Umgang mit Gesundheitsdaten eine Brücke schlagen kann zwischen Wissenschaft, Versorgung und Beteiligung. Sie macht deutlich, wie relevant Transparenz, intelligente Nutzung und gesellschaftliche Kommunikation für eine zukunftsfähige Gesundheitsforschung sind.Aufgezeichnet im HealthCare MakerMobil auf der DMEA 2025.Schreibt uns Eure Kommentare gerne an MehrEinsatzWagen@healthcarefuturists.com und vernetzt euch mit uns auf unseren Social Media Kanälen.

Virtual Course: November 6-8, 2025 (Course #2503269) Learn more and register at https://www.aaos.org/education/courses/2503269-3345/ Course Directors: J. Mark Melhorn MD FAAOS, Marilyn L. Yodlowski MD PhD FAAOS, and Barry Gelinas MD DC FIAIME Supplemental articles: Review article “A Comprehensive Review of Injury Causation Analysis Methodology for the Assessment of Workers' Compensation and Motor Vehicle Collision Injuries” from the March 1, 2025 issue. JAAOS Global Research article “Workers' Compensation: The Burden on Healthcare Resource Utilization After Foot and Ankle Surgery” from the December, 2023 issue. Research article “The Influence of Workers' Compensation Status on Patient-Reported Outcomes after Cervical Disc Arthroplasty at an Ambulatory Surgical Center” from the September 1, 2023 issue. AAOS Now article “Why Workers' Compensation Expertise Still Matters for Orthopaedic Surgeons” 17:16-2023. AAOS Now article “Workers' Compensation Cases: Learn the Differences between ‘Medically Necessary,' ‘Reasonable,' and ‘Appropriate'” 15:28-29, 2021.   The JAAOS Journal Club podcast series is brought to you by the Journal of the American Academy of Orthopaedic Surgeons and the AAOS Resident Assembly. The opinions expressed in the podcast are those of the speakers and not necessarily those of AAOS. The opinions, information, and discussions presented in the podcast are for general informational and educational purposes only.  The podcast is not intended to provide legal advice as each case and jurisdiction will vary.  Medical professionals should consult with their own attorney or an attorney involved in the claims process to address questions or concerns about any legal aspects associated with the patient evaluation.

In this episode, Dr. Valentin Fuster presents new research revealing that fewer than one-third of patients with hypoplastic left heart syndrome survive 35 years without a transplant, though many adults report good to excellent quality of life after stage reconstructive surgery. Highlighting expert insights, he underscores the urgent need for innovative treatments and dedicated care teams to improve long-term outcomes in this high-risk congenital heart disease.

Fidelia Cascini is Digital Healh expert engaged by the Italian Ministry of Health on European and national initiative. She recently wrote a book on secondary use of data in healthcare, read it here: Secondary Use of Electronic Health Data Public Health Perspectives, Use Cases and Challenges https://link.springer.com/book/10.100... This conversation covers the categorization of electronic health data, the importance of distinguishing different data types, and the potential applications and challenges in digital health. We also explore healthcare systems' digitalization, patient data privacy, the European Health Data Space (EHDS), and future public health perspectives. Learn about patient-generated data, clinical trials, and the significant role of digital health advancements in shaping the future of healthcare. www.facesofdigitalhealth.com Newsletter: https://fodh.substack.com/ Youtube: https://www.youtube.com/watch?v=tbSCXUhIDZ8 Show notes: 01:08 Diving into Different Categories of Health Data 01:35 Discussion on Secondary Use of Data in Europe 02:16 Call for Listener Feedback 03:07 Starting the Interview with Felia Kini 03:36 Importance of Distinguishing Data Types 04:38 Challenges in Using Different Data Sources 06:38 Real-World vs. Clinical Trial Data 07:19 Patient Preferences and Medication Adherence 09:31 Most Suitable Data for Secondary Purposes 10:32 Patient Generated Health Data 11:53 Discussions Among Health Ministries 13:09 Trustworthiness and Integration of Digital Tools 17:45 Patient Reported Outcomes in EHRs 19:35 European Health Data Space (EHDS) 29:55 Patient Control Over Data 33:47 Barriers to EHDS Success 37:13 Public Health Perspectives and Global Changes 40:14 Conclusion and Future Perspectives 42:20 Closing Remarks and Upcoming Events

Fidelia Cascini is Digital Healh expert engaged by the Italian Ministry of Health on European and national initiative. She recently wrote a book on secondary use of data in healthcare, read it here: Secondary Use of Electronic Health Data Public Health Perspectives, Use Cases and Challenges https://link.springer.com/book/10.100... This conversation covers the categorization of electronic health data, the importance of distinguishing different data types, and the potential applications and challenges in digital health. We also explore healthcare systems' digitalization, patient data privacy, the European Health Data Space (EHDS), and future public health perspectives. Learn about patient-generated data, clinical trials, and the significant role of digital health advancements in shaping the future of healthcare. www.facesofdigitalhealth.com Newsletter: https://fodh.substack.com/ Youtube: https://www.youtube.com/watch?v=tbSCXUhIDZ8 Show notes: 01:08 Diving into Different Categories of Health Data 01:35 Discussion on Secondary Use of Data in Europe 02:16 Call for Listener Feedback 03:07 Starting the Interview with Felia Kini 03:36 Importance of Distinguishing Data Types 04:38 Challenges in Using Different Data Sources 06:38 Real-World vs. Clinical Trial Data 07:19 Patient Preferences and Medication Adherence 09:31 Most Suitable Data for Secondary Purposes 10:32 Patient Generated Health Data 11:53 Discussions Among Health Ministries 13:09 Trustworthiness and Integration of Digital Tools 17:45 Patient Reported Outcomes in EHRs 19:35 European Health Data Space (EHDS) 29:55 Patient Control Over Data 33:47 Barriers to EHDS Success 37:13 Public Health Perspectives and Global Changes 40:14 Conclusion and Future Perspectives 42:20 Closing Remarks and Upcoming Events

Five articles from the April 2025 issue summarized in five minutes, with the addition of a brief editorial commentary. The 5-in-5 feature is designed to give readers an overview of articles that may pique their interest and encourage more detailed reading. It may also be used by busy readers who would prefer a brief audio summary in order to select the articles they want to read in full. The featured articles this month are, “The Glycogen Synthase Kinase–3 Inhibitor CHIR99021 Reduces Fatty Infiltration and Muscle Atrophy After Rotator Cuff Tears: An In Vitro Experiment and In Vivo Mouse Model,” “Kinesiophobia and High-Impact Sport Activity Are Associated With a Reduced Rate of Return to Sport After High Tibial Osteotomy: A Risk Factor Analysis of a Young and Active Population,” “Outcomes of Revision Elbow Medial Ulnar Collateral Ligament Reconstruction in Professional Baseball Players: An Analysis of 191 Pitchers From 2010 to 2023,” “The Chance to Become an Elite Athlete After Pediatric And Adolescent Anterior Cruciate Ligament Reconstruction,” and “Analyzing the Association of the Area Deprivation Index on Patient-Reported Outcomes in Patients Undergoing Hip Arthroscopy.” Click here to read the articles.

In today's episode, we'll discuss time-limited triplet therapy in relapsed or refractory CLL. Zanubrutinib, venetoclax and obinutuzumab induced deep remissions, and was well tolerated, even in very high-risk patients, and those with prior exposure to targeted therapies. After that: researchers chronicle the development of a patient-reported outcome measure for sclerosis associated with chronic GVHD—graft-versus-host disease. The new symptom scale—currently undergoing validation studies—may provide valuable information regarding severity, functional impact, and response to therapy. Finally, a study of changes in population dynamic rates that underlie inflammation-associated myeloid bias. The work demonstrates the use of mathematical models to deliver critical biological insights and uncover underlying mechanisms.Featured Articles:MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trialDevelopment of the Lee Symptom Scale–Skin Sclerosis for chronic GVHD–associated sclerosisPopulation dynamics modeling reveals that myeloid bias involves both HSC differentiation and progenitor proliferation biases

In this video discussion with JACC: Associate Editor Michelle M. Kittleson, MD, PhD, FACC, and authors Eric Hall, MD and James A. de Lemos, MD, FACC, they review this study published in JACC & presented at ACC.25. Do patients who survive cardiogenic shock have neurocognitive consequences at intermediate-term follow-up? New cognitive impairment is common at discharge and 3 months after CS and is associated with worse quality of life and functional status. #jacc #jaccjournals #acc25

Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, the conversation covered a discussion on the longer-term impact of bimekizumab on patient-reported outcomes, health-related QoL, and work productivity in patients with active PsA who were bDMARD-naïve or had an inadequate response to TNFis for up to 1 year.

The imPROVE study aims to bridge the gap in patient-reported outcomes (PRO) data for Black women with breast cancer by enhancing engagement with tailored electronic PROs (ePROs) and partnering with community leaders to address barriers and ensure accessibility and relevance in community cancer care settings. In this episode, CANCER BUZZ speaks with Manraj Kaur, PhD, investigator and lead faculty for research and innovation at Patient-Reported Outcomes, Value, and Experience (PROVE) center at Mass General Brigham and Andrea Pusic, MD, chief of division of plastic and reconstructive surgery, director of PROVE center at Mass General Brigham, and professor of surgery at Harvard Medical School about the imPROVE study's efforts to enhance Black women's engagement in ePROs in breast cancer treatment.  Dr. Kaur sheds light on strategies to improve technology accessibility for Black women in their cancer care center by providing iPads and refined usability features on the imPROVE app. Dr. Pusic highlights imPROVE implementation results at five community cancer centers, including utilizing local champions and equitable access to resources.   “When we make sure Black women are included, we gain a more accurate picture of health, we can design better care, and then we take a real step towards closing the health equity gap.” – Manraj Kaur   “The imPROVE study is all about increasing accessibility of patient-reported outcome measurements to Black breast cancer patients receiving care in community cancer centers.” – Andrea Pusic   Manraj Kaur, PhD   Investigator, Lead Faculty for Research and Innovation Patient-Reported Outcomes Value Experience (PROVE) Center  Brigham and Women's Hospital  Boston, MA    Andrea Pusic, MD  Chief of Division of Plastic and Reconstructive Surgery  Director, PROVE Center  Brigham and Women's Hospital  Professor of Surgery  Harvard Medical School  Boston, MA    Resources: ACCC imPROVE Study Blog - https://www.accc-cancer.org/acccbuzz/blog-post-template/accc-buzz/2024/06/18/the-power-of-patient-reported-outcome-measures-to-community-cancer-centers? Harvard/BWH PROVE Center - https://prove.bwh.harvard.edu/current_project/improve-breast-cancer-care/

Podcast Overview The podcast, hosted by Valentin Fuster on January 21, 2025, provides an in-depth review of the FINEARTS-HF trial, which evaluated the efficacy of the non-steroidal mineralocorticoid receptor antagonist finerenone in patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). The episode highlights findings published in the Journal of the American College of Cardiology (JACC). Introduction to the FINEARTS-HF Trial (00:03:19 – 00:05:56) The FINEARTS-HF trial demonstrated that finerenone reduced heart failure events by 16% compared to placebo in patients with HFmrEF/HFpEF. However, cardiovascular death rates were similar between groups, making the overall clinical impact moderate. Finerenone's Impact on Quality of Life (00:05:59 – 00:12:46) The trial assessed quality of life using the Kansas City Cardiomyopathy Questionnaire (KCCQ), revealing only a slight improvement (1.62 points) with finerenone. Critics, including the FDA, questioned the clinical relevance of these results and suggested the need for simpler, more meaningful patient-reported outcome measures. Finerenone in Patients with Recent Worsening Heart Failure (00:12:58 – 00:20:30) Patients with recent worsening heart failure showed a greater absolute benefit from finerenone, as they were at higher risk of recurrent events and cardiovascular death. However, further studies are needed to confirm these findings. Finerenone's Role in Obese Patients with HFmrEF/HFpEF (00:20:31 – 00:25:20) In obese patients, the benefits of finerenone were consistent across body mass index (BMI) categories, with a possible greater effect in those with higher BMI. Nevertheless, the reliance on BMI as a metric for obesity was criticized, and alternative measures were recommended. Finerenone and Kidney Outcomes (00:25:23 – 00:40:52) Finerenone showed a modest reduction in albuminuria but did not significantly alter kidney disease progression. Initial declines in glomerular filtration rate (GFR) were noted but should not automatically lead to discontinuation of therapy. Mixed findings highlight the need for more research to understand its renal effects. Conclusion (00:40:54 – 00:44:05) The FINEARTS-HF trial was recognized as a landmark study, showcasing modest benefits of finerenone in a challenging patient population. The podcast calls for continued research to refine quality of life metrics, better understand obesity's role in HFmrEF/HFpEF, and explore finerenone's long-term renal and cardiovascular impacts.

In this episode, hosts Drs. Jason Silverman and Peter Lu sit down with Dr. Vicky Ng to discuss outcomes following pediatric liver transplantation beyond survival. In particular, we review the importance of hearing the patient voice using the PeLTQL, a disease-specific health related quality of life instrument. Dr. Ng is a Professor of Pediatrics at the University of Toronto, Medical Director of the Paediatric Liver Transplantation Transplant and Regenerative Medicine Centre at SickKids Hospital and current President of NASPGHAN. Learning objectives:To understand the benefits of developing a condition-specific health-related quality of life (HRQOL) tool using the Pediatric Liver Transplantation Quality of Life questionnaire (PeLTQL) as a model.To review pre- and post-transplant factors that may impact the HRQOL of pediatric liver transplant recipients.To explore the benefits of the patient (and caregiver) voices in truly understanding important patient outcomes.Links:Development and Validation of the Pediatric Liver Transplantation Quality of Life: A Disease-Specific Quality of Life Measure for Pediatric Liver Transplant RecipientsBarriers to ideal outcomes after pediatric liver transplantationFeasibility of using a patient-reported outcome measure intoclinical practice following pediatric liver transplantation: TheStarzl Network experienceJennifer Vittorio - Healthcare Transitions in Pediatric Liver Transplantation (Special JPGN Episode) - Position paperSupport the showThis episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

The December 2024 replay wraps up the year with five previously posted episodes on autoimmune neurology. The episode begins with Drs. Michael R. Wilson and John Pluvinage discussing transcobalamin antibodies. The episode leads into an interview with Dr. Andrew McKeon, who talks about paraneoplastic CAMKV autoimmune encephalitis. In the third episode, Dr. Maarten Titulaer discusses long-term outcomes and rehab in NMDAR encephalitis. The episode continues with Prof. Zsolt Illes discussing the mortality of patients with AQP4 antibody–seropositive neuromyelitis optica spectrum disorder compared with that in the general population. In the final episode, Drs. Marius Ringelstein and Ilya Ayzenberg discuss the effectiveness and safety of Eculizumab in routine clinical care. Podcast Links: Transcobalamin receptor Antibodies in Autoimmune Vitamin B12 Central Deficiency  Paraneoplastic CAMKV Autoimmune Encephalitis Long-Term Outcomes and Rehabilitation in Anti-NMDAR Encephalitis Mortality in a Danish NMO Cohort Eculizumab Use in Neuromyelitis Optica Spectrum Disorders Article Links: Transcobalamin Receptor Antibodies in Autoimmune Vitamin B12 Central Deficiency  Paraneoplastic Calmodulin Kinase-Like Vesicle-Associated Protein (CAMKV) Autoimmune Encephalitis  Long-Term Cognitive, Functional, and Patient-Reported Outcomes in Patients With Anti-NMDAR Encephalitis  Mortality of the Danish Nationwide AQP4 Antibody-Seropositive Neuromyelitis Optica Spectrum Disorder Patient Cohort  Eculizumab Use in Neuromyelitis Optica Spectrum Disorders: Routine Clinical Care Data From a European Cohort Disclosures can be found at Neurology.org.

In this episode of the Award-winning PRS Journal Club Podcast, 2024 Resident Ambassadors to the PRS Editorial Board – Rami Kantar, Yoshi Toyoda, and Amanda Sergesketter- and special guest, Jeffrey Marcus, MD, discuss the following articles from the October 2024 issue: “Aesthetic Outcomes in Cleft Care: Exploring Patterns in Patient-Reported Outcomes across Adolescence” Dunworth, Hernandez, Ching, et al. Read the article for FREE: https://bit.ly/AdolescenceCleftCare Special guest, Dr. Jeffrey Marcus, is Professor and chief of the Division of Plastic, Maxillofacial, and Oral Surgery at Duke University. He obtained his medical degree at the University of Michigan followed by plastic surgery residency at Northwestern and fellowships in both pediatric plastic surgery and craniofacial surgery at the University of Toronto Sick Kids. His clinical interests focus on cleft and craniofacial surgery, facial paralysis, and rhinoplasty. He is the past president of the Rhinoplasty Society and the recipient of numerous grants and patents in craniomaxillofacial surgery. READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCOct24Collection

Dr. Tesha Monteith discusses the Neurology article, "Effect of Ubrogepant on Patient-Reported Outcomes When Administered During the Migraine Prodrome: Results From the Randomized PRODROME Trial" by Richard B. Lipton and colleagues, available in the September 24th issue of Neurology or at neurology.org.  Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209745

This week, Circulation is proud to present the 4th annual Disparities issue. First, Guest Editor Latha Palaniappan leads the interview with author Jennifer Green as they discuss the article "Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes Trial." Then, Disparities Editor Mercedes Carnethon talks with author Benjamin Zielonka about his article "Childhood Opportunity and Acute Interstage Outcomes: A National Pediatric Cardiology Quality Improvement Collaborative Analysis." Finally, Dr. Karol Watson leads the discussion with author Lisa Cooper regarding her article "Equitable Care for Hypertension: Blood Pressure and Patient-Reported Outcomes of the RICH LIFE Cluster Randomized Trial." For the episode transcript, visit: https://www.ahajournals.org/do/10.1161/podcast.20240712.517573

This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!

As the need and demand for quality care increases, time in clinic needs to become more efficient. Working smarter, not harder, is a daily challenge for all in our field. With mobile technology streamlining so much and improvements in patient reported outcome (PRO) collection among patients with rheumatoid arthritis (RA) needed, it had Dr. Daniel Solomon asking “...is there an app for that?”. Today, we review the study A Mobile Health Application Integrated in the Electronic Health Record for Rheumatoid Arthritis Patient–Reported Outcomes: A Controlled Interrupted Time-Series Analysis of Impact on Visit Efficiency , recently published in Arthritis & Rheumatology. Our guest, Dr. Daniel Solomon, is our guest and the study's first author. 

Incorporating Patient-Reported Outcomes in Oncology Research: Elaine Novakovich and Theresa Yu by i3 Health

Jennifer Petrillo Billet PhD is an Executive Director and Program Lead for investigational dalzanemdor, or SAGE-718, at Sage Therapeutics. She is responsible for driving the global development strategy, including delivery of the right evidence for key stakeholders including regulators, payers, and providers, and patients. Dalzanemdor is being evaluated for indications in Huntington's Disease, Alzheimer's Disease, and Cognitive Impairment in Parkinson's Disease. Jennifer has 20 years of deep expertise in the measurement science of Clinical Outcomes Assessments (COAs) and significant experience in all phases of drug development. Jennifer received her Bachelors in Economics at Virginia Tech, and her PhD from the London School of Hygiene and Tropical Medicine (LSHTM). She has published and presented extensively on health economics and outcomes research topics, and clinical research, across a range of leading journals and conferences.

Patient-reported outcomes (PROs) have become increasingly integral in healthcare for assessing the effectiveness of treatments from the patient's perspective. It sounds like a reasonable step in improving clinical research and care provision, but gathering data can be more difficult then you may think. It isn't easy to get to marginalized communities. There are language barriers in collecting data. There are cultural aspects that impact responses. So, how can you design useful electronic solutions for patient-reported outcomes? Hear from Mustafa Ali Syed, Researcher at the Manchester Academic Health Science Centre, The University of Manchester, and Ben James, Co-founder/Chief Design Officer at uMotif - ePRO, an engagement platform designed to power clinical and real-world research. Both are co-authors of a recently published paper titled Exploring the Cross-cultural Acceptability of Digital Tools for Pain Self-reporting. www.facesofdigitalhealth.com Newsletter: https://fodh.substack.com/ Show notes: 00:00:00 Why Do PROs Matter? 00:04:00 Evolution of Data Collection 00:06:00 Importance of Diversity in Clinical Trials 00:08:00 Ethnicity, Culture, and Pain Perception 00:12:00 The Role of Technology in PROs 00:14:00 Designing Inclusive Digital Solutions 00:20:00 Challenges in Engaging Targeted Populations 00:22:00 Language and Communication Barriers 00:26:00 The Future of PRO Research

Despite our technological advances in ACL surgery, the rehabilitation period remains challenging, particularly when it comes to lingering quadriceps weakness. Blood Flow Restriction (BFR) Therapy has been introduced as a potential means to speed up the return of quad function. We welcome Dr. Kelechi Okoroha from the Mayo Clinic to discuss his high-level study, “Effects of Perioperative Blood Flow Restriction Therapy Program on Early Quadriceps Strength and Patient-Reported Outcomes After Anterior Cruciate Ligament Reconstruction.” By utilizing BFR in both the pre- and post-operative periods following ACL reconstruction, Dr. Okoroha and his team did demonstrate a benefit in strength and patient reported outcomes.

In this episode, we discuss top abstracts in the myeloid space from the American Society of Hematology 2023 meeting with Dr. Anand Patel. Here are the abstracts that were discussed:1. TRANSFORM-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis https://ash.confex.com/ash/2023/webprogram/Paper173509.html 2. MANIFEST-2: Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study https://ash.confex.com/ash/2023/webprogram/Paper179141.html 3. Venetoclax + Decitabine vs 7+3 in AML https://ashpublications.org/blood/article/142/Supplement%201/970/503790/Comparing-the-Efficacy-and-Safety-of-Venetoclax 4. FILO study: Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. https://ash.confex.com/ash/2023/webprogram/Paper185437.html  5. AUGMENT-101: Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results https://ash.confex.com/ash/2023/webprogram/Paper172422.html 6. VEN+HMA in HR MDS: Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study https://ash.confex.com/ash/2020/webprogram/Paper139492.html

In this episode, we talk about GVHD prophylaxis, including recent data on post-transplant cyclophosphamide and abatacept with Dr. Shernan Holtan from the University of Minnesota. Here are the key trials we discussed:1. BMT CTN 1203 trial: Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of GVHD in allogeneic transplantation. https://pubmed.ncbi.nlm.nih.gov/30824040/ 2. BMT CTN 1703 study: Post-Transplantation Cyclophosphamide-Based GVHD prophylaxis  https://pubmed.ncbi.nlm.nih.gov/37342922/ 3. Patient-Reported Outcomes of BMT CTN 1703 https://ash.confex.com/ash/2023/webprogram/Paper187859.html 4. Phase II Study of Myeloablative 7-8/8-Matched Allotransplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil https://pubmed.ncbi.nlm.nih.gov/37311510/ 5. BMT CTN 1301 trial: Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies https://pubmed.ncbi.nlm.nih.gov/34855460/ 6. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD (ABA2) https://pubmed.ncbi.nlm.nih.gov/33449816/ 7. Aurora Kinase a Inhibition for Gvhd and Relapse Prevention after Allogeneic HCT: Phase I Trial in Combination with Ptcy/Sirolimus https://ash.confex.com/ash/2023/webprogram/Paper181292.html

According to the CDC, 36 million falls are reported each year, resulting in 3 million adults being transported to the Emergency Room and 32,000 adults dying from their falls. Studies have shown that, in any six-month period, more than 50% of the people living with MS fall at least once, and 30% fall multiple times. As falls at home are common, occupational therapist Tracy Carrasco joins me to share tips and strategies for making your home safe and accessible. We're also sharing a research roundup featuring results from a few different clinical trials that are focused on the impact of diet on MS. And that includes the Swank diet, the Wahls diet, the Mediterranean diet, and a simple low-fat diet. We'll tell you about a novel study that explored the economic impact of an Epstein-Barr Virus vaccine on the cost of MS care in Australia. If you're living with MS, we have your invitation to participate in the Patient Reported Outcomes for Multiple Sclerosis (PROMS) initiative survey. And we'll tell you how you can catch the video replay of the International Progressive MS Alliance global webcast on research and treatment for cognitive challenges in progressive MS. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: Some of the things I'm thankful for  :22 Research Roundup: The impact of diet on MS  2:40 Survey results show how an EBV vaccine could impact the cost of MS care in Australia  9:03 If you're living with MS, here's your invitation to participate in the PROMS initiative online survey  12:22 How to catch the video replay of the International Progressive MS Alliance global webcast about research and treatment for cognitive challenges in progressive MS 13:38 Tracy Carrasco shares tips for making your home safe and accessible 15:25 Share this episode  27:26 Have you downloaded the free RealTalk MS app?  27:46 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/325 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com STUDY: A Low-Fat Diet Improves Fatigue in Multiple Sclerosis: Results from a Randomized Controlled Trial https://journals.sagepub.com/doi/10.1177/13524585231208330 STUDY: Diet-Induced Changes in Functional Disability are Mediated by Fatigue in Relapsing-Remitting Multiple Sclerosis: A Secondary Analysis of the WAVES Randomized Parallel-Arm Trial https://journals.sagepub.com/doi/full/10.1177/20552173231209147 STUDY: Exploring the Cost-Effectiveness of EBV Vaccination to Prevent Multiple Sclerosisin an Australian Setting https://jnnp.bmj.com/content/early/2023/11/02/jnnp-2023-332161 PARTICIPATE: The PROMS Initiative Survey https://proms-initiative.org/survey-proms VIDEO: Cognitive Challenges in Progressive MS https://youtube.com/watch?v=bN26GrRZMts Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 325 Guest: Tracy Carrasco Privacy Policy

Host Liana Tedesco, MD Guest interviewee Melissa Wright, MD, discussing her clinical practice guideline “Summary on the Treatment of Clavicle Fractures” from the September 15, 2023 issue (https://journals.lww.com/Jaaos/toc/2023/09150) Articles summarized from the September 1, 2023 issue (https://journals.lww.com/Jaaos/toc/2023/09010) Review article “Applications of Augmented Reality in Orthopaedic Spine Surgery” Research article “The Influence of Workers' Compensation Status on Patient-Reported Outcomes after Cervical Disc Arthroplasty at an Ambulatory Surgical Center” Article summarized from the September 15, 2023 issue (https://journals.lww.com/Jaaos/toc/2023/09150) Research article “Fellowship-Trained Orthopaedic Trauma Surgeons Achieve Better Postoperative Radiographic Parameters After Intramedullary Nailing of Intertrochanteric Femur Fractures when Compared With Non-trauma–Trained Surgeons” Follow this link to download these and other articles from the September 1, 2023 issue of JAAOS (https://journals.lww.com/Jaaos/toc/2023/09010) and the September 15, 2023 issue of JAAOS (https://journals.lww.com/Jaaos/toc/2023/09150). The JAAOS Unplugged podcast series is brought to you by the Journal of the American Academy of Orthopaedic Surgeons and the AAOS Resident Assembly.

In a world where patients were often lost in a sea of opinions, Dr. Karthik Anantharaman dared to dream of a different reality. Little did he know, his journey to improve patient outcomes would take an unexpected turn. As he delved into the world of data, he discovered a powerful tool that could unlock the potential of personalized medicine. But what he didn't anticipate was the profound impact it would have on not just individual patients, but on the entire healthcare ecosystem. With every step he took, the possibilities seemed endless, leaving us wondering: What other surprises lay hidden in the realm of data-driven patient care?Episode Timeline:[00:04:26] - Putting Patients First[00:07:25] - Leveraging Technology[00:12:05] - Telehealth Services[00:15:59] - Global Expansion[00:17:13] - The Importance of Tracking and Analyzing Teleconferencing[00:19:32] - Leveraging Data for Personalized Medicine[00:21:49] - The Power of Data in Generating Insights[00:23:19] - Patient Reported Outcomes and Technology[00:28:27] - Contacting Apollo Hospitals‌Links:Dr. Karthik Anantharaman:  https://in.linkedin.com/in/karthikanantharamanReady to magnify your HealthTech journey's impact?Tune in

In a world where patients were often lost in a sea of opinions, Dr. Karthik Anantharaman dared to dream of a different reality. Little did he know, his journey to improve patient outcomes would take an unexpected turn. As he delved into the world of data, he discovered a powerful tool that could unlock the potential of personalized medicine. But what he didn't anticipate was the profound impact it would have on not just individual patients, but on the entire healthcare ecosystem. With every step he took, the possibilities seemed endless, leaving us wondering: What other surprises lay hidden in the realm of data-driven patient care? Episode Timeline: [00:04:26] - Putting Patients First [00:07:25] - Leveraging Technology [00:12:05] - Telehealth Services [00:15:59] - Global Expansion [00:17:13] - The Importance of Tracking and Analyzing Teleconferencing [00:19:32] - Leveraging Data for Personalized Medicine [00:21:49] - The Power of Data in Generating Insights [00:23:19] - Patient Reported Outcomes and Technology [00:28:27] - Contacting Apollo Hospitals ‌Links: Dr. Karthik Anantharaman:  https://in.linkedin.com/in/karthikanantharaman Ready to magnify your HealthTech journey's impact? Tune in

"It's July 2022. This morning I tried to donate my kidney, this afternoon the transplant team told me that I can't, I have cancer." Words no one wants to hear. Even for a former Jeopardy! champion with degrees in molecular biology and two decades of experience in the biopharma industry, the implications of the phrase are overwhelming.Nearly a year later, our flagship podcast host Jeff Stewart is telling his story.Today, Nick Kenny, Chief Scientific Officer at Syneos Health, turns the tables on Jeff, interviewing him on his recent experience being diagnosed and undergoing treatment for two separate cancers. They discuss the realities today for patients like Jeff who are dealing with complex cancer diagnoses—including information overload both fake and real, and the importance of “pre-bunking”—and his newly released book, Living: Inspiration from a Father with Cancer.At a time when regulators in our industry at large are increasingly and rightly focused on patient perspectives in drug development, and with ASCO, the single largest global gathering of about 50,000 clinical cancer experts right around the corner in early June, this is a very timely discussion.Read excerpts of the book on NPR.Check out our other content on the patient experience:Webinar: Patient Perspectives as Essential in Next-Generation Clinical TrialsExploring the Value and Impact of Patient-Reported Outcomes in Patient-Centric CAR-T Clinical Trials3 Ways Patient Voice is Impacting Rare Disease Research, According to AdvocatesThe views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Commentary by Dr. Valentin Fuster

Chadi hosts a duo of Canadiens to discuss quality of life and patient-reported outcomes in clinical trials: Christopher Booth, MD, and Michael Brundage, MSc, FRCPC, MD, both of Queen's University. They begin by pontificating on whether quality of life is a “must” endpoint in designing interventional clinical trials today, the timeline of how “PROs” came to be a term and an important component of clinical trials, how PRO measures should differ across disease types and trials, and how PROs should be approached from an organizational and operational standpoint. Then, they discuss and use examples to illustrate how practical it is for providers to regularly measure quality of life and PROs, how payers should be approached for discussion on PRO measures, whether toxicity of therapies are underestimated by providers, and a whole lot more. Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on Youtube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

In this episode of the Award-winning PRS Journal Club Podcast, 2023 Resident Ambassadors to the PRS Editorial Board – Rami Kantar, Yoshi Toyoda, and Ronnie Shammas- and special guest Nicholas Haddock, MD, discuss the following articles from the April 2023 issue: “Paravertebral Blocks in Tissue Expander Breast Reconstruction: A Propensity-Matched Analysis of Perioperative Opioid Consumption and Patient-Reported Outcomes” by Shamsunder, Chu, Taylor, et al. Read the article for FREE: https://bit.ly/ParavertebralBlock Special guest Nicholas Haddock, MD, is a microsurgeon who completed his residency training at NYU, followed by a microsurgery fellowship at the University of Pennsylvania. He is an Associate Professor in the Department of Plastic Surgery and the Department of Orthopedic Surgery at UT Southwestern Medical Center and is a pioneer in microsurgical breast reconstruction and efficiency in breast reconstructive surgery. He also serves as an Associate Editor for the Plastic and Reconstructive Surgery Journal. READ the articles discussed in this podcast as well as free related content from the archives: https://bit.ly/JCApril23Collection

In this week's episode, we'll be looking at a paper recently published in “ACR Open Rheumatology” titled: “Machine Learning Applied to Patient-Reported Outcomes to Classify Physician-Derived Measures of Rheumatoid Arthritis Disease Activity“. This study used machine learning tools to investigate whether longitudinal patient-reported outcome data can be a proxy for Clinical Disease Activity Index (CDAI), presenting interesting findings that may impact the practice of rheumatology.  Our guest this week is the paper's first author, Dr. Jeffrey Curtis. Dr. Curtis is the Marguerite Jones Harbert – Gene V. Ball Endowed Professor in Rheumatology and Immunology at the University of Alabama at Birmingham. He has many accolades to his name, including being a prior winner of the Henry Kunkel Young Investigator Award and being a member of the American Society for Clinical Investigation. 

Dr. Baumhauer is a tenured Professor and serves as the Senior Associate Dean of Academic Affairs for the University of Rochester School of Medicine and Dentistry. She also is the Associate Chair of Academic Affairs within the Department of Orthopaedics at the University of Rochester. In addition to providing clinical care and performing surgery, she holds the position as the Director of the Clinical Health Informatics Core for the UR Healthcare System and is a board of director of Accountable Health Partners, ACO for the Rochester Region. She received her Doctorate of Medicine from the University of Vermont College of Medicine. She completed orthopaedic residency at the Medical Center Hospital of Vermont and a Fellowship in Foot and Ankle Surgery at the Medical College of Wisconsin. She also completed a Masters in Public Health degree from the University of Rochester. Dr. Baumhauer is the past president of the American Board of Orthopaedic Surgery, American Orthopaedic Foot and Ankle Society (AOFAS), and Eastern Orthopaedic Association. She currently is the President of the Patient-Reported Outcomes Measurement Information System (PROMIS) Health Organization and has published over two hundred peer reviewed papers and book chapters. In Part 2, Dr. Baumhauer described research showing that patients who were able to report at times that were important to the patient ended up visiting the emergency room less and were experiencing more favorable outcomes. She discussed how data are used. The first time seeing a patient, it is important to know what their baseline values are, e.g., mild depression and moderate symptoms for physical function and pain. Trends can be noted that make it possible before meeting with a patient to look at the PROMIS scores and be able to anticipate how much time to spend with this individual. It enables the physician to triage, which patients appreciate. Patients also are asked anchoring questions, such as general health status questions that make it possible to link the medical visit. An example is are you worse, better, or the same since your last visit? Another question is can you live with your symptoms? She also discussed how patients can ask questions, such as whether there will be substantial improvement as a result of surgery. If such an outcome is unlikely, surgery should not occur. Another question patients ask is which of various treatment options should be selected? It is important to know what the patient wants to measure.

Dr. Baumhauer is a tenured Professor and serves as the Senior Associate Dean of Academic Affairs for the University of Rochester School of Medicine and Dentistry. She also is the Associate Chair of Academic Affairs within the Department of Orthopaedics at the University of Rochester. In addition to providing clinical care and performing surgery, she holds the position as the Director of the Clinical Health Informatics Core for the UR Healthcare System and is a board of director of Accountable Health Partners, ACO for the Rochester Region. She received her Doctorate of Medicine from the University of Vermont College of Medicine. She completed orthopaedic residency at the Medical Center Hospital of Vermont and a Fellowship in Foot and Ankle Surgery at the Medical College of Wisconsin. She also completed a Masters in Public Health degree from the University of Rochester. Dr. Baumhauer is the past president of the American Board of Orthopaedic Surgery, American Orthopaedic Foot and Ankle Society (AOFAS), and Eastern Orthopaedic Association. She currently is the President of the Patient-Reported Outcomes Measurement Information System (PROMIS) Health Organization and has published over two hundred peer reviewed papers and book chapters. Part 1:  Data are needed to help understand how a patient is feeling and functioning to implement preventive health strategies, maximize healthy behaviors, assess their treatment response, and understand how health care resources are being allocated. Dr. Baumhauer defined a patient reported outcome as information directly reported by the patient who experiences it and is not interpreted as when we usually obtain some health history and tell it in our terms and report it into the patient's note. She provided examples of the disconnect between what is important to the patient and what the clinician believes is important for the patient. A validated number can be placed on how the patient is feeling and functioning. It is important that a validated instrument be used that is quick and does not hold up the clinician. At the University of Rochester, they landed on the use of PROMIS (Patient-Reported Outcomes Measurement Information System) on a custom platform called UR VOICE (Validated Outcomes in Clinical Experience). They collect the same information for each patient. They try to ask the right questions when the information is needed most. The aim is to be domain specific, such as symptom-based, using the core package of pain, physical function, and depression rather than focusing on various diseases. Depending on the medical specialty, the symptoms emphasized can be different. Compared to SF-36, PROMIS is a better measure since it is more responsive to change.